References in periodicals archive ?
USA], Dec 12 (ANI): Increasing physical activity has a positive impact on survival in lymphoma patients, finds a study.
It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
The primary gastrointestinal non-Hodgkin's lymphoma is a rare entity.
The US Food and Drug Administration (FDA) has approved US-based Kite Pharma's chimeric antigen receptor T cell therapy, Yescarta (axicabtagene ciloleucel), intended for the treatment of relapsed or refractory large B-cell lymphoma in adult patients who had at least two lines of systemic therapy, it was reported on Friday.
Every 28 minutes someone is diagnosed with lymphoma.
T-cell/histiocyte-rich large B-cell lymphoma is an unusually encountered lymphoid neoplasm of stomach with aggressive course, and is an uncommon morphologic variant of diffuse large B-cell lymphoma.
Coordinated by the University of Southampton, this unique collaborative project aims to allow doctors to rapidly determine the precise genetic signature of a patient s lymphoma and then find drugs tailor-made to target the genetic faults driving the cancer.
Non-Hodgkin lymphomas can occasionally present with morphologic features that resemble classical Hodgkin lymphoma.
The objective of the study was to determine the frequency and pattern of Non Hodgkin's lymphoma (NHL) in adults in a tertiary care hospital.
ON average, every 40 minutes in the UK, somebody is diagnosed with lymphoma.
Background: Although oral cavity squamous cell carcinoma is a major health problem in India, oral cavity non-Hodgkin's lymphoma (NHL) is very rare.
Approximately 25% of all cases of extranodal non-Hodgkin lymphoma (NHL) occur in the head and neck region; NHL of the external auditory canal (EAC) and thyroid gland are rare.

Full browser ?